NCT05102045

Brief Summary

Objectives: The purpose of this study was to investigate the effects of high-frequency repetitive Transcranial Magnetic Stimulation (rTMS) in Alzheimer's Disease (AD). Methods: Twenty-seven AD patients aged ≥60 years were included in the study and divided into 3 groups (rTMS, Aerobic Exercise (AE) and control). All groups received pharmacological treatment. rTMS group (n=10) received 20 Hz rTMS treatment on bilateral dorsolateral prefrontal cortex, 5 days a week over 2 weeks, and AE group (n=10) received the moderate-intensity aerobic exercise for 50 min sessions, 5 days a week over 2 weeks. Control group (n=10) was only treated pharmacologically. Neuropsychiatric and behavioral status, cognition, balance, functional mobility, and quality of life, and functional brain changes were evaluated before and after the treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at below P25 for not_applicable alzheimer-disease

Timeline
Completed

Started Sep 2016

Shorter than P25 for not_applicable alzheimer-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2017

Completed
4.2 years until next milestone

First Submitted

Initial submission to the registry

August 3, 2021

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 1, 2021

Completed
Last Updated

November 1, 2021

Status Verified

October 1, 2021

Enrollment Period

8 months

First QC Date

August 3, 2021

Last Update Submit

October 21, 2021

Conditions

Keywords

Alzheimer's DiseaseRepetitive Transcranial Magnetic StimulationCognitive FunctionAerobic ExerciseFunctional MRIResting State Networks

Outcome Measures

Primary Outcomes (1)

  • Functional Magnetic Resonance Imaging

    Resting state networks and activation areas in the brain were evaluating with Functional Magnetic Resonance Imaging

    4 weeks after baseline

Secondary Outcomes (7)

  • Neuropsychometric test battery

    4 weeks after baseline

  • Mini Mental State Examination Test

    4 weeks after baseline

  • Neuropsychiatric Inventory Questionnaire

    4 weeks after baseline

  • Berg Balance Scale

    4 weeks after baseline

  • Timed Up and Go Test

    4 weeks after baseline

  • +2 more secondary outcomes

Study Arms (3)

TMS group

EXPERIMENTAL

In the TMS group (n=10) rTMS was applied to the bilateral dorsolateral prefrontal cortex (DLPFC) at 20 Hz, for 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.

Device: Repetitive Transcranial Magnetic StimulationDrug: Acetylcholinesterase InhibitorsDrug: Memantine

AE group

EXPERIMENTAL

AE group (n=9) received a moderate- intensity aerobic exercise program lasting 50 minutes per session, 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.

Other: Aerobic ExerciseDrug: Acetylcholinesterase InhibitorsDrug: Memantine

Control group

ACTIVE COMPARATOR

No additional intervention was given to the patients in the control group (n=8) and participants were only treated pharmacologically.

Drug: Acetylcholinesterase InhibitorsDrug: Memantine

Interventions

TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.

TMS group

Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.

AE group

Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.

AE groupControl groupTMS group

Memantine were given for Alzheimer's disease. .

AE groupControl groupTMS group

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • having clinical AD diagnosis according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) criteria
  • being 60 years and older
  • having Clinical Dementia Rating Scale (CDR) scores 1 or 2
  • living independently

You may not qualify if:

  • not being able to walk independently,
  • having physical disabilities,
  • having a history of alcohol / substance abuse,
  • having head trauma
  • having epileptic seizures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul Medipol University

Istanbul, Beykoz, Turkey (Türkiye)

Location

Related Publications (1)

  • Budak M, Bayraktaroglu Z, Hanoglu L. The effects of repetitive transcranial magnetic stimulation and aerobic exercise on cognition, balance and functional brain networks in patients with Alzheimer's disease. Cogn Neurodyn. 2023 Feb;17(1):39-61. doi: 10.1007/s11571-022-09818-x. Epub 2022 May 30.

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Transcranial Magnetic StimulationExerciseCholinesterase InhibitorsMemantine

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeuticsMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaEnzyme InhibitorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesCholinergic AgentsNeurotransmitter AgentsPhysiological Effects of DrugsAmantadineAdamantaneBridged-Ring CompoundsHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 3, 2021

First Posted

November 1, 2021

Study Start

September 1, 2016

Primary Completion

May 1, 2017

Study Completion

June 1, 2017

Last Updated

November 1, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations